2. Academic Validation
  3. Design, Synthesis and Anti-Inflammatory Evaluation of 3-Substituted 5-Amidobenzoate Derivatives as Novel P2Y14 Receptor Antagonists via Structure-Guided Molecular Hybridization

Design, Synthesis and Anti-Inflammatory Evaluation of 3-Substituted 5-Amidobenzoate Derivatives as Novel P2Y14 Receptor Antagonists via Structure-Guided Molecular Hybridization

  • J Med Chem. 2025 Feb 13;68(3):2483-2503. doi: 10.1021/acs.jmedchem.4c01539.
Shuqiang Mao 1,  Wenjin Liu 2,  Xin Wang 1,  Mingzhu Wang 3,  Simin Wang 1,  Yongfang Yao 2 4 5,  Yongtao Duan 3,  Chuanjun Song 1 4
Affiliations

Affiliations

  • 1 College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
  • 2 Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
  • 3 Henan Provincial Key Laboratory of Pediatric Hematology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou 450018, China.
  • 4 Pingyuan Laboratory, Zhengzhou 450001, China.
  • 5 State Key Laboratory of Esophageal Cancer Prevention & Treatment; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China.
PMID: 39878051 DOI: 10.1021/acs.jmedchem.4c01539
Abstract

The P2Y14R is activated by UDP and UDP glucose and is involved in many human inflammatory diseases. Based on the molecular docking analysis of currently reported P2Y14R antagonists and the crystallographic overlap study between PPTN and compound IV, a series of 3-substituted 5-amidobenzoate derivatives were designed, synthesized, and identified as promising P2Y14R antagonists. The optimal compound 45 (methyl 3-(1H-benzo[d]imidazol-2-yl)-5-(2-(p-tolyl) acetamido)benzoate, IC50 = 0.70 ± 0.01 nM) showed a strong binding ability to P2Y14R, high selectivity, moderate oral bioactivity, and improved pharmacokinetic profiles. In the LPS-induced acute lung injury model, compound 45 demonstrated significant anti-inflammatory efficacy, effectively mitigating the pulmonary infiltration of immune cells and inflammatory response through suppressing the NLRP3 signaling pathway. Thus, 45 with potent P2Y14R antagonistic activity, in vitro and vivo efficacy, and favorable druggability can be a strategy for treating acute lung injury and can be optimized in further studies.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z